Ajanta Pharma
NSE: AJANTPHARM · ISIN INE031B01049 · Healthcare
₹3,342.70+4.50 (+0.13%)
Monday 9 November, 12:19 IST. Delayed. Source: Yahoo Finance.
Price chart
₹3,342.70 +4.50 (+0.13%) today
The day
- Previous close
- ₹3,338.20
- Open
- ₹3,344.00
- Day high
- ₹3,410.40
- Day low
- ₹3,280.00
Listed on NSE since 29 May 2000.
Key numbers
- Market value
- ₹41,333 Cr
- P/E (trailing)
- 32.75
- EPS (trailing)
- ₹101.01
- Price to book
- 8.51
- Dividend yield
- 1.93%
- Return on equity
- 27.5%
- Debt to equity
- 0.03
- Profit margin
- 20.3%
- Beta
- 0.23
- Volume today
- 84,627
- Average volume
- 1.13 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹3,707.52 Cr | ₹587.98 Cr |
| FY24 | ₹4,161.59 Cr | ₹816.17 Cr |
| FY25 | ₹4,587.51 Cr | ₹920.39 Cr |
| FY26 | ₹5,407.26 Cr | ₹1,056.00 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹1,794 Cr | ₹388 Cr | +49.2% |
| Q1 FY27Apr–Jun 2026 | ₹1,626 Cr | ₹330 Cr | +29.2% |
| Q4 FY26Jan–Mar 2026Audited | ₹1,422 Cr | ₹267 Cr | +18.4% |
| Q3 FY26Oct–Dec 2025 | ₹1,375 Cr | ₹274 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹1,354 Cr | ₹260 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹1,303 Cr | ₹255 Cr | – |
Source: Ajanta Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Ajanta Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹2,110 Cr | ₹1,984 Cr |
| Investments | ₹620 Cr | ₹588 Cr |
| Inventories | ₹967 Cr | ₹939 Cr |
| Owed by customers | ₹1,864 Cr | ₹1,854 Cr |
| Cash and equivalents | ₹90 Cr | ₹103 Cr |
| Total assets | ₹6,425 Cr | ₹6,155 Cr |
| Borrowings | ₹104 Cr | ₹212 Cr |
| Total liabilities | ₹1,567 Cr | ₹1,628 Cr |
| Shareholders’ equity | ₹4,858 Cr | ₹4,527 Cr |
Source: Ajanta Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Ajanta Pharma
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 10,421
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Ajanta Pharma in the last day or two.
Dividends and corporate actions
All companies- Interim Dividend - Rs 32 Per Share
Dividend · ex-date 5 August 2026
- Interim Dividend - Rs 28 Per Share
Dividend · ex-date 10 November 2025
- Interim Dividend - Rs 28 Per Share
Dividend · ex-date 6 November 2024
- Buy Back
Buyback · ex-date 30 May 2024
- Interim Dividend - Rs 26 Per Share
Dividend · ex-date 8 February 2024
- Interim Dividend - Rs 10 Per Share/Special Dividend - Rs 15 Per Share
Dividend · ex-date 4 August 2023
- Buy Back
Buyback · ex-date 24 March 2023
- Interim Dividend - Rs 7 Per Share
Dividend · ex-date 11 November 2022 · record date 14 November 2022
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.